Admedus Charts An Eclectic Path To A Global Future
Executive Summary
There are not many companies whose R&D business model combines immunotherapies and a medtech cardio franchise, but for Australia’s Admedus it’s a plan that is working so far. And more original science could be added to the portfolio as the company moves increasingly away from its S&D roots.
You may also be interested in...
China Market Growth Spurs Siemens Healthineers To Restructure Asia Ops
Germany-headquartered Siemens Healthineers has uncoupled China from the rest of its Asia business to maximize opportunities in the world’s largest medtech market-in-waiting.
Putting The E In ESG: A Global Medtech’s Approach To Meeting The Climate Challenge
The pressures on global medtechs to focus more on sustainability are internal as well as external. Scope 3 adds yet another layer of compliance. Johnson & Johnson’s EMEA VP for Surgical Vision Erin McEachren explains to In Vivo how her organization meets these challenges while simultaneously addressing EU Medical Device Regulation requirements and ensuring patient safety standards.
Putting The E In ESG: The Provider’s View Of Sustainability Compliance
As the health care sector moves from linear to circular, medtechs, providers and patients all have roles to play in ensuring that current strategies, practices and behaviors contribute to guarantee a sustainable future. Part one of a short series on this theme looks as best practice for providers.